On the stock market since 2017, it operates in the world of health and science. It has 29 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 59% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 37.7× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 20% of them.
Analysts' average target sits 69% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $7.1M a year. A small number, but proof the product has real buyers.
There is $145.7M in the vault; even if every debt were paid off, $145.7M would remain.
A loss of $20.6M against $7.1M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 1/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 20/100.
On our five-subject report card, WHWK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: WHWK is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (20/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.